According to THE SAGE GROUP, 1 Million or More Japanese Citizens Suffer From Critical Limb Ischemia (CLI)

A new analysis published by THE SAGE GROUP concludes that atherosclerotic peripheral arterial disease (PAD) afflicts 8-10 million in Japan.

“Although it is commonly believed that PAD is a ‘Western’ disease with a significantly lower prevalence in Asians, our research indicates this is not the case,” stated Mary L. Yost, President of THE SAGE GROUP. “We believe that PAD prevalence is only modestly lower. For various reasons, it has generally been underestimated in Japan.”

As with other cardiovascular diseases, age, smoking, diabetes, hypertension, high cholesterol, chronic kidney disease, race and family history are the key PAD and CLI risk factors. The relative risk of PAD increases 2X-3X with every decade, current smoking increases the risk 2X-5X and diabetes 2X-4X. Furthermore, PAD is more virulent in diabetics. Diabetics tend to have more severe ischemia, a greater number of amputations, higher mortality, and die at a younger age.

Commenting on risk factors in Japan, Yost observed, “Over the last several decades, the prevalence of diabetes has risen significantly. Japan has a high percentage of younger-onset diabetes, which increases the risk of cardiovascular complications, including PAD. In addition, the population is quite elderly (the oldest in the world) with a high prevalence of other PAD risk factors, including hypertension, smoking and chronic kidney disease. Current smoking is much more prevalent in Japan than in the U.S.”

“Unless the Japanese people have some type of genetic protection against the adverse impact of atherosclerotic risk factors, the prevalence of PAD is likely reasonably similar to that in other populations,” she concluded.

About the Report: Japan Peripheral Artery Disease and Critical Limb ischemia Prevalence and Incidence of

The report contains a comprehensive analysis of the current prevalence of diabetes, PAD and CLI in Japan. PAD and CLI prevalence and incidence are estimated for 2015-2030. The number of patients with intermittent claudication is also included in the analysis of symptomatic disease.

Additional information: http://thesagegroup.us/pages/reports/japan-pad-cli.php.

THE SAGE GROUP, a research and consulting company, specializes in peripheral vascular disease in the lower limbs, specifically chronic venous disease (CVD), PAD, CLI, intermittent claudication (IC), diabetic foot ulcers (DFU) and the costs and consequences of amputation. Additional information: www.thesagegroup.us.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170522005860/en/